Home   /  Find a Trial  /  See All TrialsHELP /  AYUDA /  求助 : (415) 476-5777 | Click to print page Print
 

See All Trials

QuickViews

Match by Tumor Type:

Newly Diagnosed (Stage I-III)
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)
Inflammatory Breast Cancer
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)

View by Trial Type:

Treatment:

 

Non-Treatment:

see All Trials

Sort by zip code:  

 

Share

Facebook
Twitter
Twitter

 
Screening

Studying New Options for Breast Cancer Screening

Simulated Screening Study of Combined Digital X-Ray, Ultrasound and Photoacoustic Breast Imaging (NCT01807754)

Summary

Digital mammography and hand-held ultrasound are commonly used to find and evaluate breast masses. However, they often result in false positive results, which require further follow-up tests. Digital breast tomosynthesis (DBT) is a new breast imaging system. Studies suggest it may help doctors more effectively pinpoint the size, shape and location of a breast mass. Three-dimensional automated ultrasound (AUS) is another type of imaging system. It uses sound waves to create 3-D images of breast tissue. Photoacoustic imaging, another technique, uses laser light to create temperature changes in the breast that can be detected by small microphones placed against the skin. In this study, women who have had an abnormal mammogram will have all three imaging tests—DBT, AUS and photoacoustic imaging. The researchers will compare the test results to see if the call back rate differs when using the DBT result alone compared to using the results from all three tests.
This is a Phase O trial

What's Involved    Contact information

MRI in Women Who are Healthy, High Risk or Have Breast Cancer

Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants (NCT00474604)

Summary

Magnetic Resonance Imaging (MRI) is a sensitive method for detecting breast cancer that has been useful in evaluating women who are at high risk for breast cancer. In addition to standard MRI, three new methods are currently being studied: Magnetic Resonance Spectroscopy (MRS) provides information about the chemical make-up of the tumor tissue, Dynamic Contrast-Enhanced MRI (DCE-MRI) uses faster imaging and a contrast material to provide information about the tumor's blood vessels, and Diffusion-weighted MRI (DW-MRI) creates images that provide information about the tumor tissue. This study will compare how well these three different MRI methods find and characterize breast tumors, compared to standard MRI. Women who have been recently diagnosed or suspected to have breast cancer, as well as healthy volunteers, are eligible for this study.

What's Involved    Contact information

Information About Mammography Screening for Women Age 75 and Older

Randomized Trial of a Mammography Decision Aid for Women Aged 75 and Older (NCT02198690)

Summary

It is not known whether the benefits of mammography screening outweigh the risks in women age 75 and older. To improve older women's understanding of the benefits and risks of mammography screening, researchers have developed a pamphlet that provides information about mammography specifically for this age group. This study is investigating whether the pamphlet improves older women's decision-making about mammography screening. To be eligible, women must be between the ages of 75 and 89.

What's Involved    Contact information

Comparison of Whole Breast Screening Ultrasound and Contrast Enhanced Mammography

Comparison of Whole Breast Screening Ultrasound and Contrast Enhanced Mammography for Supplemental Breast Cancer Screening (NCT02310698)

Summary

Researchers are trying to identify the best imaging technologies to use along with mammography. Breast ultrasound is sometimes used as an additional test. Studies have shown that it can detect cancers that are not seen on regular mammography. Contrast Enhanced Digital Mammography (CEDM) is an FDA-approved form of mammography. It uses a dye injected into a vein to "highlight" areas of increased blood supply, which may indicate the presence of cancer cells. CEDM has been shown to detect cancer cells that are not seen on a regular mammogram. This study is comparing the effectiveness of CEDM and breast ultrasound when used along with mammography. To be eligible, a woman must be scheduled to receive contrast enhanced digital mammography alone or with whole breast screening ultrasound or full field digital mammography on the same day or within 30 days of one another.

What's Involved    Contact information

A Blood Test for Circulating Tumor Cells for Cancer Screening

Circulating Tumor Cells (CTCs): A Potential Screening Test for Clinically Undetectable Breast Carcinoma (NCT01322750)

Summary

Scientists are trying to identify effective new techniques for breast cancer screening. Researchers now believe that breast cancer cells can leave the breast and move through the blood stream to other parts of the body before the tumor is even clinically detectable. Reliable and accurate detection of these circulating tumor cells (CTCs) is now possible with a simple blood test. The goal of this research is see whether a blood test for CTCs could provide a simple, reliable, cost-effective form of breast cancer screening. The aim of this specific study is to evaluate whether individuals with CTCs and no other signs of malignancy have clinically undetectable breast cancer. To be eligible, participants must be military health care beneficiaries.

What's Involved    Contact information

Breast Cancer Screening with Ultrasound and Mammography

Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Screening Mammography, Including Cost Comparisons (NCT00649337)

Summary

Abnormalities can be more difficult to detect on a mammogram when women have dense breast tissue. Ultrasound imaging is a noninvasive medical test that produces a picture of the internal structures of the breast and is used to complement other screening tests, such as mammography. SonoCine is an innovative exam that uses a standard ultrasound machine to take a video of the entire breast. The purpose of this study is to determine whether adding whole breast ultrasound with SonoCine to annual screening mammography is more effective in women with dense breast tissue than mammography alone. To be eligible, participants must not have had a screening mammogram within 10 months of study entry or have been diagnosed with breast cancer within the last year.

What's Involved    Contact information

Using DWI with MRI for Breast Cancer Detection

A MULTI-CENTER STUDY EVALUATING THE UTILITY OF DIFFUSION WEIGHTED IMAGING FOR DETECTION AND DIAGNOSIS OF BREAST CANCER (NCT02022579)

Summary

Magnetic resonance imaging (MRI) is currently used to screen high-risk women. Diffusion-weighted imaging (DWI) calculates a measure of how water moves through tissue. Because water moves at different rates through healthy breast tissue and cancerous breast tissue, incorporating DWI into conventional breast MRI may decrease false positives and reduce preventable biopsies. In this study, researchers will investigate the accuracy of MRI combined with DWI in women with breast tumors that were identified on MRI. The DWI will be done at the time of the MRI, adding an additional two minutes to the MRI procedure.

What's Involved    Contact information

Contrast-Enhanced Spectral Mammography and MRI for Screening High-Risk Women

Dual-energy Contrast-enhanced Digital Subtraction Mammography (CESM) as a Tool to Screen High Risk Women for Breast Cancer: a Comparison to Screening Breast MRI (NCT02275871)

Summary

Mammography is the recommended screening test for early breast cancer detection. Magnetic Resonance Imaging (MRI) is recommended as an additional screening tool for some women who are at high risk of developing breast cancer. Contrast-Enhanced Spectral Mammography (CESM) is an FDA approved tool used to identify inconclusive findings on a mammogram or ultrasound because it shows areas of increased blood supply that are typical of breast tumors. Early studies suggest CESM may be better than MRI for screening high-risk women. In this study, high-risk women will receive both MRI and CESM so that researchers can determine which improves early detection.

What's Involved    Contact information

A Blood Test for Breast Cancer Detection

Free Fatty Acid Metabolite Biomarkers for Cancer (NCT01692951)

Summary

Scientists are trying to develop a blood test for breast cancer detection. Free fatty acid metabolites are small molecules produced by tumors. Researchers have developed a blood test that can identify six cancer-related metabolites. This study is looking at whether the test can accurately detect breast cancer. To be eligible, a woman must be having a breast biopsy or breast cancer surgery. (The blood test may also identify lung and colon tumors and patients with these types of cancers are also being enrolled in this study.)

What's Involved    Contact information

A New Type of MRI for Breast Cancer Screening

High Resolution 3D Diffusion-weighted Breast MRI (NCT01315106)

Summary

High resolution 3D diffusion-weighted breast MRI is a new technique for breast cancer screening. Diffusion-weighted breast imaging develops a picture of the breast by assessing the random motion of water molecules in breast tissue. Researchers have found that water diffusion is abnormal in breast tumors. This leads them to believe that diffusion-weighted imaging may provide a new way to identify breast tumors. In this study, women will have a standard breast MRI and then an MRI using the new technique. The images from both MRIs will be compared with the results of the pathology report, allowing the researchers to determine which technique identifies more breast tumors.

What's Involved    Contact information